With the rapid development of technology, the biomedical field has an increasingly urgent need for accurate and efficient bioelectrical potential measurement technologies. Bioelectrical potential measurement technologies such as electroencephalogram (EEG) and electrocardiogram (ECG) play a crucial role in the diagnosis of neurological diseases and cardiac health monitoring. However, traditional analog-to-digital converters (ADCs) often face challenges such as high noise interference, insufficient resolution, and high power consumption when processing bioelectrical potential signals, thus limiting the further development of bioelectrical potential measurement technologies.

CoreBai Microelectronics has keenly captured this market pain point, with its profound technical heritage and innovation ability in analog and mixed-signal integrated circuits, meticulously crafted the CBM24AD99Q analog-to-digital converter. The advent of this product aims to provide a high-performance, low-noise, and highly integrated solution in the field of bioelectrical potential measurement, promoting biomedical engineering technology to new heights and contributing to the cause of human health.

1. Product Overview

The CBM24AD99Q is a low-noise 24-bit synchronous sampling Δ-Σ analog-to-digital converter (ADC) designed specifically for bioelectrical potential measurement applications such as electroencephalogram (EEG) and electrocardiogram (ECG). It features a built-in programmable gain amplifier (PGA), an internal voltage reference, and an oscillator, enabling the realization of a highly integrated medical instrument system with lower size, power consumption, and cost. It adopts advanced Δ-Σ modulation technology and combines a highly integrated circuit design, integrating core functional modules such as the programmable gain amplifier (PGA), internal voltage reference, and internal oscillator into one. This highly integrated design not only significantly reduces the system volume and cost but also remarkably improves the system's reliability and stability.

The product has a multi-channel synchronous sampling function and can simultaneously collect multiple bioelectrical potential signals, fully meeting the urgent need for multi-channel data acquisition in modern biomedical measurement. The data rate of the product can be flexibly adjusted within the range of 250 SPS to 16k SPS, allowing users to freely select the data rate according to the actual application scenario to achieve the optimal balance between performance and power consumption.

2. Core Technologies and Innovation Highlights

(1) Low-noise performance: The CBM24AD99Q achieves extremely low input-referred noise through optimized circuit design and advanced process technology. Its input-referred noise is as low as 1 μVPP (70Hz BW), enabling accurate capture of weak bioelectrical potential signals and laying a solid foundation for subsequent signal processing and analysis.

(2) High common-mode rejection ratio: In bioelectrical potential measurement, common-mode interference signals are a key factor affecting measurement accuracy. The CBM24AD99Q has a common-mode rejection ratio as high as -110 dB, effectively suppressing common-mode interference signals, ensuring the purity and stability of the measurement signal, and enhancing the reliability of the measurement results.

(3) Programmable gain amplifier: The product has up to 8 low-noise PGAs built-in, and the gain of each PGA can be flexibly programmed and set between 1, 2, 4, 6, 8, 12, or 24. This enables the product to adapt to bioelectrical potential signals of different amplitudes without the need for an external amplification circuit, further simplifying the system design and reducing cost and power consumption.

(4) Built-in high-precision oscillator: The CBM24AD99Q has a highly frequency-stable oscillator integrated internally, providing a reliable clock signal for the normal operation of the product. Compared with an external clock source, the built-in oscillator can significantly simplify the system design process and effectively reduce the interference and noise brought by the external clock source, thus comprehensively improving the overall performance of the system.

(5) Flexible power management: This product supports single-polar or bipolar power supply. The analog power supply AVDD voltage range is 4.5V to 5.5V, and the digital power supply DVDD voltage range is 1.8V to 3.3V. In addition, it is equipped with flexible power-down and standby modes. Users can precisely control the power consumption of the chip according to the actual application requirements, thereby further extending the service life of battery-powered devices. In standby mode, it has extremely low power consumption, effectively reducing system energy consumption.

3. Product Performance Parameters

5. Product Application Areas

(1) The CBM24AD99Q, as an analog front-end product with all the commonly used functions required for extracranial electroencephalogram (EEG) and electrocardiogram (ECG) applications, its high resolution and low-noise performance enable it to accurately capture the subtle changes of brain waves. With its high integration and excellent performance, the CBM24AD99Q can create a variety of scalable medical instrument systems, providing strong support for the diagnosis and research of neurological diseases. For example, in the research of neurological diseases such as epilepsy and Alzheimer's disease, the CBM24AD99Q can assist researchers in obtaining more accurate and detailed electroencephalogram data, deeply understanding the pathogenesis and pathological characteristics of the disease, and providing an important basis for the early diagnosis and treatment of the disease.

(2) Electrocardiogram (ECG) monitoring: It realizes high-precision acquisition and processing of electrocardiogram signals. By real-time monitoring of changes in electrocardiogram signals, doctors can timely detect abnormal conditions of heart diseases, such as arrhythmia and myocardial infarction, and take corresponding treatment measures. Compared with traditional electrocardiogram monitoring devices, the equipment equipped with the CBM24AD99Q is superior in accuracy and reliability, bringing a more excellent medical service experience to patients.

(3) Sleep research monitor: The CBM24AD99Q can be applied to sleep research monitors, accurately capturing various bioelectrical potential signals during sleep, including key data such as electroencephalogram, electrocardiogram, and electrooculogram. Through in-depth analysis of signals related to sleep disorders, researchers can better understand the physiological process of sleep and the formation mechanism of sleep disorders, which provides a scientific basis for the formulation of clinical diagnostic criteria for sleep disorders and the optimization of treatment strategies.

(4) Other bioelectrical potential measurement applications: In addition to the above application fields, the CBM24AD99Q can also be widely used in other bioelectrical potential measurement fields such as electromyogram (EMG) and evoked potential (EP). In these applications, the high performance and flexibility of the CBM24AD99Q can meet different measurement needs, providing strong support for biomedical research and clinical diagnosis.

The CBM24AD99Q, as a meticulously crafted work of Corebai , with its outstanding performance, advanced technology, and broad application prospects, has set a new paradigm in the field of bioelectrical potential measurement. Electroencephalogram and electrocardiogram, as representatives of bioelectrical potential measurement technologies, their wide application and importance in clinical diagnosis have injected strong impetus into the development of biomedical engineering technology. With the continuous progress of technology, these technologies are expected to achieve greater breakthroughs in the diagnosis and analysis of epilepsy, intracranial lesions, brain disease assessment, sleep disorder diagnosis, and arrhythmia and myocardial infarction. In the future, Corebai will continue to uphold the spirit of innovation, continuously improve product performance and quality, provide customers with better products and services, and contribute to the development of the global biomedical cause.